C-X-C Chemokine Receptor Type 1 - Pipeline Review, H2 2019
C-X-C Chemokine Receptor Type 1 - Pipeline Review, H2 2019
SUMMARY
C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) pipeline Target constitutes close to 11 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report C-X-C Chemokine Receptor Type 1 - Pipeline Review, H2 2019, outlays comprehensive information on the C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) - C-X-C Chemokine Receptor Type 1 is a receptor for interleukin 8 (IL8). It binds to IL8 with high affinity, and transduces the signal through a G-protein-activated second messenger system. This response is mediated via a G-protein that activates a phosphatidylinositol-calcium second messenger system. This receptor binds to IL-8 with a high affinity and to MGSA (GRO) with a low affinity. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 1 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Respiratory, Central Nervous System, Dermatology and Metabolic Disorders which include indications Autoimmune Disorders, Bronchopulmonary Dysplasia, Chronic Obstructive Pulmonary Disease (COPD), Colorectal Cancer, Hepatocellular Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Inflammation, Inflammatory Pain, Liver Transplant Rejection, Lung Cancer, Melanoma, Metastatic Colorectal Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Melanoma, Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Pancreatic Cancer, Pancreatic Islet Transplant Rejection, Post-Operative Pain, Pulmonary Inflammation, Triple-Negative Breast Cancer (TNBC), Type 1 Diabetes (Juvenile Diabetes) and Uveal Melanoma.
Furthermore, this report also reviews key players involved in C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
SUMMARY
C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) pipeline Target constitutes close to 11 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report C-X-C Chemokine Receptor Type 1 - Pipeline Review, H2 2019, outlays comprehensive information on the C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) - C-X-C Chemokine Receptor Type 1 is a receptor for interleukin 8 (IL8). It binds to IL8 with high affinity, and transduces the signal through a G-protein-activated second messenger system. This response is mediated via a G-protein that activates a phosphatidylinositol-calcium second messenger system. This receptor binds to IL-8 with a high affinity and to MGSA (GRO) with a low affinity. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 1 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Respiratory, Central Nervous System, Dermatology and Metabolic Disorders which include indications Autoimmune Disorders, Bronchopulmonary Dysplasia, Chronic Obstructive Pulmonary Disease (COPD), Colorectal Cancer, Hepatocellular Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Inflammation, Inflammatory Pain, Liver Transplant Rejection, Lung Cancer, Melanoma, Metastatic Colorectal Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Melanoma, Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Pancreatic Cancer, Pancreatic Islet Transplant Rejection, Post-Operative Pain, Pulmonary Inflammation, Triple-Negative Breast Cancer (TNBC), Type 1 Diabetes (Juvenile Diabetes) and Uveal Melanoma.
Furthermore, this report also reviews key players involved in C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1)
- The report reviews C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) targeted therapeutics and enlists all their major and minor projects
- The report assesses C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) - Overview
C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) - Companies Involved in Therapeutics Development
Dompe Farmaceutici SpA
Eli Lilly and Co
Merck & Co Inc
Rise Biopharmaceutical Ltd
Syntrix Biosystems Inc
Vaccibody AS
C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) - Drug Profiles
DF-2755A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ladarixin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3041658 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
navarixin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PAC-G31P - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Antagonize CXCR1 and CXCR2 for Pancreatic Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
reparixin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SX-517 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SX-576 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SX-682 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) - Dormant Products
C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) - Discontinued Products
C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) - Product Development Milestones
Featured News & Press Releases
Dec 04, 2019: Duke Health: New, non-hormonal target identified for advanced prostate cancer
Jun 20, 2019: Syntrix Pharmaceuticals announces dosing of first patient in phase 1/2 clinical trial of SX-682 in Combination with KEYTRUDA (pembrolizumab) in metastatic melanoma
Apr 08, 2019: Researchers report SX-682 could enhance multiple forms of T cell-based immunotherapies in solid tumors
Mar 26, 2019: New study points to SX-682 as strategy to boost immunotherapy effectiveness in advanced colorectal cancer
Feb 04, 2019: Syntrix wins $3.4M NIH grant to conduct phase 1/2 trial of SX-682 in Myelodysplastic Syndrome
Dec 10, 2015: Research presented at the San Antonio Breast Cancer Symposium intended to strike at the heart of cancer stem cells
Oct 05, 2015: Study Available at Fox Chase Cancer Center Evaluates the Use of Reparixin in Combination with Paclitaxel for the Treatment of Metastatic Triple Negative Breast Cancer
Oct 01, 2014: Dompe commitment in oncology against cancer stem cells
Sep 25, 2013: Pharmaceutical company Domp? launches REP0112, a trial to assess the efficacy and safety of Reparixin in autologous islet cell transplantation
Jul 10, 2013: Domp? announces innovative treatment in the fight against type 1 diabetes: pancreatic islet cell transplantation, a hope that has already come true
Dec 06, 2012: Domp? Announces Presentation Of Reparixin Clinical Trial Data In Metastatic Breast Cancer At 34th CTRC-AACR San Antonio Breast Cancer Symposium
Oct 23, 2012: Domp? Announces Enrollment Of First Patient In Phase III Trial On Reparixin
Oct 24, 2011: Domp? Announces Presentation Of Phase II Clinical Data Of Reparixin For Improvement Of Efficacy of Pancreatic Islet Transplantation At 2011 CTS-IXA Congress
Oct 13, 2011: Domp?'s Reparixin Receives EMA Orphan Drug Designation For Prevention Of Graft Rejection In Pancreatic Islet Transplantation
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) - Overview
C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) - Companies Involved in Therapeutics Development
Dompe Farmaceutici SpA
Eli Lilly and Co
Merck & Co Inc
Rise Biopharmaceutical Ltd
Syntrix Biosystems Inc
Vaccibody AS
C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) - Drug Profiles
DF-2755A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ladarixin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3041658 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
navarixin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PAC-G31P - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Antagonize CXCR1 and CXCR2 for Pancreatic Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
reparixin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SX-517 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SX-576 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SX-682 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) - Dormant Products
C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) - Discontinued Products
C-X-C Chemokine Receptor Type 1 (CDw128a or High Affinity Interleukin 8 Receptor A or IL8 Receptor Type 1 or CD181 or CXCR1) - Product Development Milestones
Featured News & Press Releases
Dec 04, 2019: Duke Health: New, non-hormonal target identified for advanced prostate cancer
Jun 20, 2019: Syntrix Pharmaceuticals announces dosing of first patient in phase 1/2 clinical trial of SX-682 in Combination with KEYTRUDA (pembrolizumab) in metastatic melanoma
Apr 08, 2019: Researchers report SX-682 could enhance multiple forms of T cell-based immunotherapies in solid tumors
Mar 26, 2019: New study points to SX-682 as strategy to boost immunotherapy effectiveness in advanced colorectal cancer
Feb 04, 2019: Syntrix wins $3.4M NIH grant to conduct phase 1/2 trial of SX-682 in Myelodysplastic Syndrome
Dec 10, 2015: Research presented at the San Antonio Breast Cancer Symposium intended to strike at the heart of cancer stem cells
Oct 05, 2015: Study Available at Fox Chase Cancer Center Evaluates the Use of Reparixin in Combination with Paclitaxel for the Treatment of Metastatic Triple Negative Breast Cancer
Oct 01, 2014: Dompe commitment in oncology against cancer stem cells
Sep 25, 2013: Pharmaceutical company Domp? launches REP0112, a trial to assess the efficacy and safety of Reparixin in autologous islet cell transplantation
Jul 10, 2013: Domp? announces innovative treatment in the fight against type 1 diabetes: pancreatic islet cell transplantation, a hope that has already come true
Dec 06, 2012: Domp? Announces Presentation Of Reparixin Clinical Trial Data In Metastatic Breast Cancer At 34th CTRC-AACR San Antonio Breast Cancer Symposium
Oct 23, 2012: Domp? Announces Enrollment Of First Patient In Phase III Trial On Reparixin
Oct 24, 2011: Domp? Announces Presentation Of Phase II Clinical Data Of Reparixin For Improvement Of Efficacy of Pancreatic Islet Transplantation At 2011 CTS-IXA Congress
Oct 13, 2011: Domp?'s Reparixin Receives EMA Orphan Drug Designation For Prevention Of Graft Rejection In Pancreatic Islet Transplantation
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Dompe Farmaceutici SpA, H2 2019
Pipeline by Eli Lilly and Co, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Rise Biopharmaceutical Ltd, H2 2019
Pipeline by Syntrix Biosystems Inc, H2 2019
Pipeline by Vaccibody AS, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Dompe Farmaceutici SpA, H2 2019
Pipeline by Eli Lilly and Co, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Rise Biopharmaceutical Ltd, H2 2019
Pipeline by Syntrix Biosystems Inc, H2 2019
Pipeline by Vaccibody AS, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Dompe Farmaceutici SpA
Eli Lilly and Co
Merck & Co Inc
Rise Biopharmaceutical Ltd
Syntrix Biosystems Inc
Vaccibody AS
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Dompe Farmaceutici SpA
Eli Lilly and Co
Merck & Co Inc
Rise Biopharmaceutical Ltd
Syntrix Biosystems Inc
Vaccibody AS
